{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:26Z","timestamp":1791932366731,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.09.037","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T07:15:55Z","timestamp":1664954155000},"page":"6599-6606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2\/3 trials"],"prefix":"10.1016","volume":"40","author":[{"given":"Jakub K.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E.","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri A.","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Grant-Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth-Ann G.","family":"Coller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolee","family":"Welebob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Grais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.037_b0005","unstructured":"WHO. Ebola virus disease (2021),<https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ebola-virus-disease> Accessed: 26 Aug 2022."},{"key":"10.1016\/j.vaccine.2022.09.037_b0010","unstructured":"FDA. FDA Approves First Treatment for Ebola Virus (2020),<https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus> Accessed: 26 Aug 2022."},{"key":"10.1016\/j.vaccine.2022.09.037_b0015","unstructured":"FDA. FDA approves treatment for ebola virus (2020),<https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-ebola-virus> Accessed: 26 Aug 2022."},{"key":"10.1016\/j.vaccine.2022.09.037_b0020","unstructured":"CDC. Ebola (Ebola Virus Disease) Prevention and Vaccine (2021),<https:\/\/www.cdc.gov\/vhf\/ebola\/prevention\/index.html> Accessed: 26 Aug 2022"},{"key":"10.1016\/j.vaccine.2022.09.037_b0025","unstructured":"Ebola in DRC: Recommendations for accelerating outbreak control. 1-4 (WHO Scientific and Technical Advisory Group for Infectious Hazards (STAG-IH), 2019)."},{"key":"10.1016\/j.vaccine.2022.09.037_b0030","unstructured":"ERVEBO\u00ae (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection Prescribing Information. (Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc., Whitehouse Station, NJ 08889, USA, 2019)."},{"key":"10.1016\/j.vaccine.2022.09.037_b0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.09.037_b0040","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2022.09.037_b0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.037_b0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.037_b0055","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.037_b0060","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged >\/=60 Years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.037_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28111-8","article-title":"Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules","volume":"8","author":"Wagner","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.037_b0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/v12050520","article-title":"The effects of pre-existing antibodies on live-attenuated viral vaccines","volume":"12","author":"Mok","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.09.037_b0075","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2020.04.066","article-title":"Humoral and cellular immune response induced by rVSVDeltaG-ZEBOV-GP vaccine among frontline workers during the 2013\u20132016 West Africa Ebola outbreak in Guinea","volume":"38","author":"Boum","year":"2020","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2022.09.037_b0080","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent ebola in liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.037_b0085","article-title":"Baseline Asymptomatic Malaria Infection and Immunogenicity of rVSVDeltaG-ZEBOV-GP Vaccine: the sierra leone trial to introduce a vaccine against ebola (STRIVE)","author":"Mahon","year":"2021","journal-title":"J Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2022.09.037_b0090","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The sierra leone trial to introduce a vaccine against ebola: an evaluation of rVSVG-ZEBOV-GP vaccine tolerability and safety during the west africa ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.037_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2022.09.037_b0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4269\/ajtmh.19-0076","article-title":"Effect of gamma irradiation on the antibody response measured in human serum from subjects vaccinated with recombinant vesicular stomatitis virus-zaire ebola virus envelope glycoprotein vaccine","volume":"101","author":"Grant-Klein","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.09.037_b0105","article-title":"A corroborating evaluation of the effects of gamma-irradiated human serum samples from rVSV\u0394G-ZEBOV-GP (V920) vaccines using a validated plaque-reduction neutralization test","author":"Grant-Klein","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"31","key":"10.1016\/j.vaccine.2022.09.037_b0110","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.09.037_b0115","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6279","key":"10.1016\/j.vaccine.2022.09.037_b0120","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2022.09.037_b0125","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.037_b0130","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","article-title":"Longitudinal analysis of the human B cell response to Ebola virus infection","volume":"177","author":"Davis","year":"2019","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.vaccine.2022.09.037_b0135","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola vaccine in africa and europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"The New England j med"},{"issue":"24","key":"10.1016\/j.vaccine.2022.09.037_b0140","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.037_b0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"The New England j med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.09.037_b0150","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.09.037_b0155","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-zaire ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.037_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05187-0","article-title":"A retrospective cohort investigation of seroprevalence of Marburg virus and ebolaviruses in two different ecological zones in Uganda","volume":"20","author":"Nyakarahuka","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.037_b0170","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3201\/eid2505.180115","article-title":"Serologic Prevalence of Ebola Virus in Equatorial Africa","volume":"25","author":"Steffen","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.037_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0923-2516(89)80112-8","article-title":"Antibody prevalence against hemorrhagic-fever viruses in randomized representative central african populations","volume":"140","author":"Gonzalez","year":"1989","journal-title":"Res Virology"},{"key":"10.1016\/j.vaccine.2022.09.037_b0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1286-4579(00)00287-2","article-title":"Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic","volume":"2","author":"Gonzalez","year":"2000","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2022.09.037_b0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/0035-9203(93)90075-2","article-title":"Hemorrhagic-fever virus activity in equatorial africa - distribution and prevalence of filovirus reactive antibody in the central-african-republic","volume":"87","author":"Johnson","year":"1993","journal-title":"T Roy Soc Trop Med H"},{"issue":"suppl_3","key":"10.1016\/j.vaccine.2022.09.037_b0190","doi-asserted-by":"crossref","first-page":"S768","DOI":"10.1093\/infdis\/jir344","article-title":"Risk Factors for Zaire ebolavirus-Specific IgG in Rural Gabonese Populations","volume":"204","author":"Nkoghe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.037_b0195","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.133","article-title":"A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection","volume":"4","author":"Bower","year":"2017","journal-title":"Sci Data"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.037_b0200","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"The Lancet Microbe"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:27Z","timestamp":1759403967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22011458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22011458"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2\/3 trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}